Skip Navigation LinksHome > May 2013 - Volume 38 - Issue 5 > Comparison of FDG PET/CT and Gadolinium-Enhanced MRI for the...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e3182817af3
Original Articles

Comparison of FDG PET/CT and Gadolinium-Enhanced MRI for the Detection of Bone Metastases in Patients With Cancer: A Meta-analysis

Duo, Jian MD, PhD*; Han, Xiuxin MD, PhD*; Zhang, Li MD; Wang, Guowen MD*; Ma, Yulin MD*; Yang, Yun MD*

Collapse Box

Abstract

Objective: At present, the differences in the efficacy between PET/CT and MRI for the detection of bone metastases in patients with cancer have not been clearly delineated. We performed a meta-analysis to compare the performance of FDG PET/CT with that of gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer.

Methods: Studies about PET/CT and MRI for the detection of bone metastases were systematically searched in the MEDLINE, EMBASE, and EBM Review databases. We calculated sensitivities, specificities, diagnostic odds ratios, positive likelihood ratios, negative likelihood ratios (NLR), and constructed summary receiver operating characteristic curves using bivariate regression models for PET/CT and MRI, respectively.

Results: Across 9 studies (1116 patients), FDG PET/CT has similar patient-based sensitivity (0.803 vs 0.837), specificity (0.989 vs 0.977), diagnostic odds ratio (309.0 vs 221.9), positive likelihood ratio (61.7 vs 37.0), and negative likelihood ratio (0.200 vs 0.167) with gadolinium-enhanced MRI. Areas under the curve with 95% confidence interval for FDG PET/CT and gadolinium-enhanced MRI were 0.99 (0.98–0.99) and 0.98 (0.97–0.99), respectively.

Conclusions: FDG PET/CT and gadolinium-enhanced MRI have excellent diagnostic performance for the detection of bone metastases in patients with cancer.

© 2013 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.